The study retrospectively reviewed every patient who underwent ablation of a biopsy-proven T1 renal cell carcinoma at the center between March 2013 and June 2023. In total, 50 ablation procedures were performed on 46 tumors in 45 patients, with a mean tumor diameter of just 2.6 centimeters. The patients were not a healthy bunch: the mean age was 70 years, ranging from 45 to 85, and the average Charlson Comorbidity Index score was 5.5, a figure that corresponds to an estimated ten-year survival of only about 21 percent. In other words, these were precisely the patients for whom major surgery carries prohibitive risk, and yet their cancer outcomes matched or exceeded those reported in surgical series.

The technical machinery behind the results is worth unpacking. Radiofrequency ablation, the workhorse of the series, uses an internally cooled 17-gauge cluster electrode perfused with chilled saline at 70 milliliters per minute, tipped with a 2.5-centimeter active segment. The device runs a 12-minute impedance-controlled program, delivering alternating current that causes ionic agitation and resistive heating in the surrounding tissue, cooking tumor cells to destruction. The number of probe placements was scaled to tumor size, and the goal was a circumferential 0.5-centimeter margin of treated tissue around the tumor, a buffer designed to catch any microscopic extension beyond the visible mass.

Microwave ablation, introduced at the center in 2018, works differently. A 14-gauge antenna emits electromagnetic waves at 2450 megahertz, causing water molecules throughout the field to oscillate and generate frictional heat directly, rather than relying on conduction from the probe. That allows higher temperatures, larger ablation zones, and shorter treatment times, with power settings of 40, 60 or 100 watts and exposure times of 5, 10 or 15 minutes adapted to the tumor dimensions measured on pre-procedural CT. Cryotherapy, used in only a single case here, employs a 14-gauge cryoprobe and two freeze-thaw cycles to kill cells through ice-crystal formation, with the advantage of real-time monitoring of the ice ball during the procedure. Notably, if a tumor sat within 1.5 centimeters of the ureter, the team chose cryoablation, since thermal energy near the collecting system risks injuring this delicate structure.

Almost all procedures, 49 of 50, were performed under general anesthesia with combined CT and ultrasound targeting by one of three fellowship-trained interventional radiologists with five to eight years of ablation experience. Technical success, meaning satisfactory completion of the planned treatment protocol, was achieved in 100 percent of cases. Primary efficacy, defined as complete eradication of the tumor on the first follow-up CT or MRI, was 94 percent: 43 of 46 tumors. Median hospital stay was a single day, and follow-up imaging with multiphasic CT or contrast-enhanced MRI was performed at 3, 6, 9 and 12 months and then annually.

The survival statistics are the headline numbers. Overall survival was 97.4 percent at one year and 88.5 percent at both three and five years. Local tumor progression-free survival stood at 100 percent at one year and 95.2 percent at three and five years. Most strikingly, cancer-specific survival at five years was 100 percent: not a single patient in the cohort died of kidney cancer. The three deaths recorded during follow-up, from COVID-19 pneumonitis, cerebrovascular accident and decompensated liver disease at 4, 29 and 31 months respectively, were all unrelated to the malignancy. Kidney function was also preserved, with no statistically significant change in serum creatinine between the pre-procedure and one-month post-procedure measurements, a critical point given that many of these patients had limited renal reserve to begin with.

Complications occurred after 8 percent of procedures, four of 50, and all four followed radiofrequency ablation. One patient developed a pneumothorax during the procedure requiring chest drain insertion; another suffered a hemothorax, also managed with a chest drain, which prolonged the hospital stay to 13 days. A third developed a perinephric collection three months after ablation, causing mild hydronephrosis that was treated with image-guided drainage and antibiotics. The fourth experienced acute urinary retention, likely related to general anesthesia, resolved with a catheter that was successfully removed 48 hours later. That complication profile compares favorably with the published literature: a systematic review covering 2,258 thermal ablations reported an overall complication rate of 16 percent and a major complication rate of 3 percent.

Perhaps the most provocative finding is the head-to-head comparison between the two heat-based modalities. Radiofrequency ablation achieved primary efficacy in 100 percent of its 28 tumors, while microwave ablation succeeded in only 82 percent of its 17, a statistically significant difference. The failure pattern was telling: tumors in which microwave ablation failed were significantly larger, with a median diameter of 3.8 centimeters versus 2.4 centimeters for those successfully treated. Only three of the 17 microwave patients failed primary treatment, so the numbers are small, but the result aligns with a well-established inverse relationship between tumor size and ablation success. Other groups have reached similar conclusions, with one study reporting that increasing tumor size more than doubled the hazard of primary efficacy failure, and another finding residual tumor rates of 5.6 percent for T1a tumors versus 19.1 percent for larger T1b lesions.

The authors, however, urge caution in interpreting the radiofrequency-versus-microwave gap. Microwave ablation was adopted at the center only in 2018, and the technology arrived with a steep learning curve. Manufacturers marketed microwave systems as less susceptible to the heat-sink effect, in which flowing blood near large vessels carries heat away from the ablation zone, and as capable of treating larger tumors faster with a single antenna. But at the time of introduction, there were no in-vivo treatment charts for the kidney; radiologists had to plan therapy using ablation measurements made on ex-vivo animal liver. Compounding the problem, the microwave antenna produces a non-spherical ablation zone that behaves differently from radiofrequency and cryotherapy probes: the distal treatment margin sits proximal to the antenna tip, whereas with radiofrequency and cryoablation the zone extends beyond the electrode tip. Misjudging that geometry, even slightly, can leave residual viable tumor at the margin, and two of the three failures in this series involved endophytic tumors abutting the collecting system, an anatomically demanding location.

The broader context matters too. Guidelines from the European Association of Urology and the American Urological Association still recommend partial nephrectomy as first-line treatment for T1 renal cell carcinoma, citing a lack of high-level evidence for ablation. But every comparison between ablation and surgery is confounded by selection bias: surgical series enroll younger, healthier patients, while ablation is disproportionately offered to the elderly and comorbid. A large retrospective comparison of 1,057 partial nephrectomies against 180 radiofrequency and 187 cryoablation cases found the surgical patients were significantly younger and healthier. Against that backdrop, the Dublin results, 100 percent technical success, 94 percent primary efficacy, 95 percent five-year local control and zero cancer deaths in a cohort averaging age 70 with heavy comorbidity, are difficult to dismiss. The study has the usual limitations of a small, single-center, retrospective design, and only six patients were followed to five years. Still, as imaging picks up ever more small, asymptomatic kidney tumors on incidental CT scans, the case for a needle-based treatment that sends patients home the next day, with their kidneys and their cancer prognosis intact, is becoming steadily harder to ignore.

Subject of Research: Image-guided thermal ablation outcomes for T1 renal cell carcinoma over ten years

Article Title: Image guided energy-based ablation of T1 renal cell cancer: a ten-year single centre experience

Article References: Ryan, J. P. C., Lynch, O. E., McGuire, B. B., & Cantwell, C. P. (2025). Image guided energy-based ablation of T1 renal cell cancer: a ten-year single centre experience. CVIR Oncology, 1(1), Article 2. https://doi.org/10.1007/s44343-025-00001-7

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00001-7

Keywords: renal cell carcinoma, tumor ablation, radiofrequency ablation, microwave ablation, cryotherapy, interventional radiology, kidney cancer, T1 tumors, overall survival, cancer-specific survival, nephron-sparing therapy, CT-guided procedures

CIPN is a debilitating condition in which chemotherapy drugs damage the peripheral nerves, most often those serving the hands and feet. Patients typically experience numbness, tingling, burning pain, and loss of fine motor control. In severe cases, the symptoms persist for months or years after treatment ends, and there is currently no approved drug that reliably prevents or reverses the damage. Because paclitaxel, a mainstay taxane chemotherapy for breast cancer, is among the most neuropathy-inducing agents in clinical use, the search for a practical preventive measure has become a major priority in supportive oncology care.

The logic behind cryotherapy is elegantly straightforward. When a patient’s hands and feet are cooled during the infusion of chemotherapy, blood vessels in those extremities constrict, a process known as vasoconstriction. This reduces local blood flow, which in turn limits the amount of drug delivered to the small nerve fibers in the fingers and toes. Cooling also slows metabolic activity in nerve tissue and may reduce the cellular uptake of taxane molecules, further protecting the delicate axons that transmit sensation. The result is a physical barrier of sorts—cold-induced starvation of the drug at precisely the sites where neuropathy strikes first.

To test whether this mechanism translates into real clinical benefit, the research team searched six major databases—Scopus, PubMed/MEDLINE, ProQuest, ScienceDirect, SAGE Journals, and the Cochrane Library—from inception to July 17, 2025, without imposing date limits or restricting inclusion to randomized designs. The protocol was prospectively registered in PROSPERO before the final search update, a practice that helps guard against selective reporting. The team ultimately included fourteen studies: twelve randomized controlled trials and two retrospective cohort studies, all involving breast cancer patients receiving paclitaxel or nab-paclitaxel with cryotherapy as the primary preventive intervention.

The headline findings come from the comparative double-arm analyses, which directly compared cryotherapy against no cooling or alternative care. Patients who used cryotherapy had roughly 55 percent lower odds of developing moderate to severe neuropathy, measured as CTCAE Grade 2 or higher, with a relative risk of 0.45 and a 95 percent confidence interval of 0.27 to 0.77, a statistically significant result. Sensory neuropathy—the numbness and tingling that most often impair daily function—was reduced even more dramatically, with a relative risk of 0.35. On a second validated instrument, the Patient Neurotoxicity Questionnaire, the risk of reaching grade D or higher total scores fell to just 0.24 of the comparator risk, again statistically significant. Motor neuropathy, by contrast, showed no significant reduction, a finding the authors note honestly rather than glossing over.

Statistical heterogeneity across the comparative trials was low to moderate, which lends credibility to the pooled estimates. Risk of bias was assessed using the Cochrane RoB 2 tool for randomized studies and ROBINS-I for the non-randomized cohorts, while the certainty of the evidence was graded with the GRADE framework. This methodological rigor matters, because meta-analyses of supportive-care interventions are frequently criticized for combining heterogeneous protocols and outcome measures. Here, the authors took the additional step of separating comparative outcomes from single-arm proportions, treating the latter as very low-certainty, purely descriptive evidence rather than folding them into the efficacy estimates.

That separation proved important. The single-arm studies, which reported neuropathy incidence in cryotherapy users without a control group, yielded a pooled CTCAE Grade 2 or higher proportion of 0.20, but with high heterogeneity and no comparator, this figure cannot demonstrate efficacy. Similarly, pooled tolerability outcomes—any adverse event at 19 percent, cold intolerance at 16 percent, and discontinuation of cryotherapy due to side effects at just 2 percent—are non-comparative and highly heterogeneous. The authors explicitly caution that these descriptive estimates should not be interpreted as proof of safety or effectiveness, a level of statistical humility that is refreshingly rare in the field.

Two clinically crucial outcomes remain unresolved. Chemotherapy dose reduction, which matters because neuropathy often forces oncologists to cut treatment short, showed a relative risk of 0.43 in favor of cryotherapy, but this estimate rested on only two studies with a confidence interval crossing unity and a p-value of 0.109. Treatment discontinuation due to neuropathy showed an even larger apparent benefit, with a relative risk of 0.22, yet the p-value of 0.163 and wide confidence intervals mean the result is underpowered and inconclusive. These are precisely the outcomes that would matter most to patients and oncologists alike, and the authors are candid that larger trials are needed before any firm claims can be made.

The practical appeal of cryotherapy is hard to overstate. Unlike pharmacological candidates such as duloxetine, which carries its own side-effect profile, cooling devices are inexpensive, non-invasive, and require no systemic exposure. The low discontinuation rate of 2 percent suggests that most patients can tolerate the discomfort of wearing frozen gloves and socks for the duration of an infusion, even if cold intolerance affects roughly one in six. For a therapy that could spare a substantial fraction of breast cancer patients from chronic numbness and pain, the risk-benefit calculus appears favorable on its face.

Still, the authors urge cautious clinical interpretation. The evidence base, while promising, is built on trials with variable cooling protocols, differing outcome instruments, and limited power for the outcomes that matter most. Standardized intervention parameters—exact temperatures, duration of cooling, and timing relative to drug infusion—have yet to be established, and until large, well-designed randomized trials confirm the effects on dose intensity and treatment completion, cryotherapy should be viewed as a promising but not yet definitive preventive strategy. What the current analysis does establish is that the biological rationale is sound, the comparative signal is consistent, and the barrier to testing at scale is remarkably low. In a field where patients have long been told to simply endure the tingling, the prospect that a pair of frozen gloves might protect the nerves that matter most is a finding worth taking seriously.

Subject of Research: Cryotherapy for preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with paclitaxel

Article Title: Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis

Article References: Prajoko, Y. W., Tjandra, K. C., Respati, D. R. P., Ar, A., Bulandari, B. L. A., Aryasatya, D. P., Rahmani, K., & Bima, R. C. S. (2026). Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16971-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16971-7

Keywords: cryotherapy, chemotherapy-induced peripheral neuropathy, breast cancer, paclitaxel, nab-paclitaxel, meta-analysis, systematic review, sensory neuropathy, supportive oncology, taxane chemotherapy, CTCAE, nerve protection